Statistical Methods in Medical Research最新文献

In disease mapping, the relative risk of a disease is commonly estimated across different areas within a region of interest. The number of cases in an area is often assumed to follow a Poisson distribution whose mean is decomposed as the product between an offset and the logarithm of the disease's relative risk. The log risk may be written as the sum of fixed effects and latent random effects. A modified Besag-York-Mollié (BYM2) model decomposes each latent effect into a weighted sum of independent and spatial effects. We build on the BYM2 model to allow for heavy-tailed latent effects and accommodate potentially outlying risks, after accounting for the fixed effects. We assume a scale mixture structure wherein the variance of the latent process changes across areas and allows for outlier identification. We propose two prior specifications for this scale mixture parameter. These are compared through various simulation studies and in the analysis of Zika cases from the first (2015-2016) epidemic in Rio de Janeiro city, Brazil. The simulation studies show that the proposed model always performs at least as well as an alternative available in the literature, and often better, both in terms of widely applicable information criterion, mean squared error and of outlier identification. In particular, the proposed parametrisations are more efficient, in terms of outlier detection, when outliers are neighbours. Our analysis of Zika cases finds 23 out of 160 districts of Rio as potential outliers, after accounting for the socio-development index. Our proposed model may help prioritise interventions and identify potential issues in the recording of cases.

Covariate-adjusted response adaptive (CARA) designs are effective in increasing the expected number of patients receiving superior treatment in an ongoing clinical trial, given a patient's covariate profile. There has recently been extensive research on CARA designs with parametric distributional assumptions on patient responses. However, the range of applications for such designs becomes limited in real clinical trials. Sverdlov et al. have pointed out that irrespective of a specific parametric form of the survival outcomes, their proposed CARA designs based on the exponential model provide valid statistical inference, provided the final analysis is performed using the appropriate accelerated failure time (AFT) model. In real survival trials, however, the planned primary analysis is rarely conducted using an AFT model. The proposed CARA designs are developed obviating any distributional assumptions about the survival responses, relying only on the proportional hazards assumption between the two treatment arms. To meet the multiple experimental objectives of a clinical trial, the proposed designs are developed based on an optimal allocation approach. The covariate-adjusted doubly adaptive biased coin design and the covariate-adjusted efficient-randomized adaptive design are used to randomize the patients to achieve the derived targets on expectation. These expected targets are functions of the Cox regression coefficients that are estimated sequentially with the arrival of every new patient into the trial. The merits of the proposed designs are assessed using extensive simulation studies of their operating characteristics and then have been implemented to re-design a real-life confirmatory clinical trial.

Linear models are extensively used in the analysis of clinical trials. However, required model assumptions (e.g. homoscedasticity) may not be satisfied in practice, resulting in low power of treatment-covariate interaction tests. Various interaction tests have been proposed to improve the efficiency of detecting differences in treatment-covariate interactions. Aiming to fundamentally improve the power of treatment-covariate interaction tests, for heteroscedasticity of treatment responses, we develop a model-based optimal randomization procedure, referred to as model-based Neyman allocation (MNA) in this article. The derived limiting allocation proportion indicates that the procedure MNA is a generalization of response-adaptive randomization targeting Neyman allocation (RAR-NA). In theory, we demonstrate that the procedure MNA can maximize the power of treatment-covariate interaction tests. The issue of sample size estimation is also addressed. Simulation studies show, in the framework of the heteroscedastic linear model, compared with Pocock and Simon's minimization method and RAR-NA, the procedure MNA has the greatest power of tests for both systematic effects and treatment-covariate interactions, even under model misspecification. Finally, the efficiency of the procedure MNA is illustrated by a hypothetical case study based on a real schizophrenia clinical trial.

Valid instrumental variables (IVs) must not directly impact the outcome variable and must also be uncorrelated with nonmeasured variables. However, in practice, IVs are likely to be invalid. The existing methods can lead to large bias relative to standard errors in situations with many weak and invalid instruments. In this paper, we derive a LASSO procedure for the k-class IV estimation methods in the linear IV model. In addition, we propose the jackknife IV method by using LASSO to address the problem of many weak invalid instruments in the case of heteroscedastic data. The proposed methods are robust for estimating causal effects in the presence of many invalid and valid instruments, with theoretical assurances of their execution. In addition, two-step numerical algorithms are developed for the estimation of causal effects. The performance of the proposed estimators is demonstrated via Monte Carlo simulations as well as an empirical application. We use Mendelian randomization as an application, wherein we estimate the causal effect of body mass index on the health-related quality of life index using single nucleotide polymorphisms as instruments for body mass index.

The difference in restricted mean survival time has been increasingly used as an alternative measure to the hazard ratio in survival analysis. Although some statistical methods have been developed for estimating the difference in restricted mean survival time adjusted for measured confounders in observational studies, the impact of unmeasured confounding on the estimate has rarely been assessed. We develop a novel sensitivity analysis for the estimate of the difference in restricted mean survival time with respect to unmeasured confounding. After formulating the sensitivity analysis problem as an optimization problem, we explain how to obtain the sensitivity range of the difference in restricted mean survival time efficiently and assess its uncertainty using the percentile bootstrap confidence interval. Analytic results are provided for some important survival settings. Simulation studies show that the proposed methods perform well in various settings. We illustrate the proposed sensitivity analysis method by analyzing data from the German Breast Cancer Study Group study.

Multistate transition models (MSTMs) are valuable tools depicting disease progression. However, due to the complexity of MSTMs, larger sample size and longer follow-up time in real-world data, the computation of statistical estimation and inference for MSTMs becomes challenging. A bounded Taylor series in Newton-Raphson procedure is proposed which leverages the uniformization technique to derive maximum likelihood estimates and corresponding covariance matrix. The proposed method, namely uniformization Taylor-bounded Newton-Raphson, is validated in three simulation studies, which demonstrate the accuracy in parameter estimation, the efficiency in computation time and robustness in terms of different situations. This method is also illustrated using a large electronic medical record data related to statin-induced side effects and discontinuation.

Joint modeling of longitudinal and survival data is increasingly used in biomedical studies. However, existing joint models are not applicable to model the longitudinal ordinal responses with non-ignorable missing values caused by the occurrence of events in a multi-state process. In this article, we introduce a joint model for longitudinal ordinal measurements and multi-state data. Our proposed joint model consists of two sub-models: a proportional odds sub-model for longitudinal ordinal measurements and a multi-state sub-model with transition-specific proportional hazards for times of transitions between different health states, both linked by shared random effects. The model parameters were estimated employing the maximum likelihood method for a piecewise constant baseline hazard function. The proposed joint model is evaluated in a simulation study and, as an illustration, it is fitted to real data from people with human immunodeficiency virus.

Cancellation or delay of non-essential medical interventions, limitation of face-to-face assessments or outpatient attendance due to lockdown restrictions, illness or fear of hospital or healthcare centre visits, and halting of research to allow diversion of healthcare resources to focus on the pandemic led to the interruption of many clinical trials during the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) pandemic. Appropriate analysis approaches are now required for these interrupted trials. In trials with long follow-up and longitudinal outcomes, data may be available on early outcomes for many patients for whom final, primary outcome data were not observed. A natural question is then how these early data can best be used in the trial analysis. Although recommendations are available from regulators, funders, and methodologists, there is a lack of a review of recent work addressing this problem. This article reports a review of recent methods that can be used in the setting of the analysis of interrupted clinical trials with longitudinal outcomes with monotone missingness. A search for methodological papers published during the period 2020-2023 identified 43 relevant publications. We categorised these articles under the four broad themes of missing value imputation, modelling and covariate adjustment, simulation and estimands. Although motivated by the interruption due to SARS-CoV-2 and the resulting disease, the papers reviewed and methods discussed are also relevant to clinical trials interrupted for other reasons, with follow-up discontinued.

Multistate models provide a useful framework for modelling complex event history data in clinical settings and have recently been extended to the joint modelling framework to appropriately handle endogenous longitudinal covariates, such as repeatedly measured biomarkers, which are informative about health status and disease progression. However, the practical application of such joint models faces considerable computational challenges. Motivated by a longitudinal multimorbidity analysis of large-scale UK health records, we introduce novel Bayesian inference approaches for these models that are capable of handling complex multistate processes and large datasets with straightforward implementation. These approaches decompose the original estimation task into smaller inference blocks, leveraging parallel computing and facilitating flexible model specification and comparison. Using extensive simulation studies, we show that the proposed approaches achieve satisfactory estimation accuracy, with notable gains in computational efficiency compared to the standard Bayesian estimation strategy. We illustrate our approaches by analysing the coevolution of routinely measured systolic blood pressure and the progression of three important chronic conditions, using a large dataset from the Clinical Practice Research Datalink Aurum database. Our analysis reveals distinct and previously lesser-known association structures between systolic blood pressure and different disease transitions.

Patient-reported outcomes (PROs) that aim to measure patients' subjective attitudes towards their health or health-related conditions in various fields have been increasingly used in randomised controlled trials (RCTs). PRO data is likely to be bounded, discrete, and skewed. Although various statistical methods are available for the analysis of PROs in RCT settings, there is no consensus on what statistical methods are the most appropriate for use. This study aims to use simulation methods to compare the performance (in terms of bias, empirical standard error, coverage of the confidence interval, Type I error, and power) of three different statistical methods, multiple linear regression (MLR), Tobit regression (Tobit), and median regression (Median), to estimate a range of predefined treatment effects for a PRO in a two-arm balanced RCT. We assumed there was an underlying latent continuous outcome that the PRO was measuring, but the actual scores observed were equally spaced and discrete. This study found that MLR was associated with little bias of the estimated treatment effect, small standard errors, and appropriate coverage of the confidence interval under most scenarios. Tobit performed worse than MLR for analysing PROs with a small number of levels, but it had better performance when analysing PROs with more discrete values. Median showed extremely large bias and errors, associated with low power and coverage for most scenarios especially when the number of possible discrete values was small. We recommend MLR as a simple and universal statistical method for the analysis of PROs in RCT settings.